233 related articles for article (PubMed ID: 29508918)
1. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
2. What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin: update on controversial issues.
Prevost N; English JC
J Pediatr Adolesc Gynecol; 2013 Oct; 26(5):290-3. PubMed ID: 24147278
[TBL] [Abstract][Full Text] [Related]
4. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT
Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214
[TBL] [Abstract][Full Text] [Related]
5. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
6. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.
Honein MA; Moore CA; Erickson JD
Drug Saf; 2004; 27(14):1069-80. PubMed ID: 15554743
[TBL] [Abstract][Full Text] [Related]
7. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
8. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
9. Women's experiences with isotretinoin risk reduction counseling.
Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
[TBL] [Abstract][Full Text] [Related]
10. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium.
Lelubre M; Hamdani J; Senterre C; Amighi K; Peres M; Schneider MP; Bugnon O; De Vriese C
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):668-673. PubMed ID: 29726056
[TBL] [Abstract][Full Text] [Related]
12. iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system.
Schonfeld TL; Amoura NJ; Kratochvil CJ
J Law Med Ethics; 2009; 37(1):104-17. PubMed ID: 19245607
[TBL] [Abstract][Full Text] [Related]
13. Possible long-term teratogenic effect of isotretinoin in pregnancy.
Malvasi A; Tinelli A; Buia A; De Luca GF
Eur Rev Med Pharmacol Sci; 2009; 13(5):393-6. PubMed ID: 19961047
[TBL] [Abstract][Full Text] [Related]
14. [Pregnancy after isotretinoin use].
Manders KC; de Vries LC; Roumen FJ
Ned Tijdschr Geneeskd; 2013; 157(41):A6567. PubMed ID: 24103139
[TBL] [Abstract][Full Text] [Related]
15. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
Brinker A; Kornegay C; Nourjah P
Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
[TBL] [Abstract][Full Text] [Related]
16. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
17. Terminations of pregnancy associated with isotretinoin use in New Zealand.
Moodie P; Jaine R; Arnold J; Metcalfe S; Bignall M; Arroll B
N Z Med J; 2011 Jul; 124(1339):59-66. PubMed ID: 21952331
[TBL] [Abstract][Full Text] [Related]
18. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
19. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
20. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero.
Lowenstein EB; Lowenstein EJ
Clin Dermatol; 2011; 29(6):652-61. PubMed ID: 22014987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
